Hindustan Bio Sciences (BOM:532041) LT-Debt-to-Total-Asset : 0.00 (As of Dec. 2023)

View and export this data going back to 1996. Start your Free Trial

What is Hindustan Bio Sciences LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Hindustan Bio Sciences's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.00.

Hindustan Bio Sciences's long-term debt to total assets ratio declined from Sep. 2022 (0.37) to Dec. 2023 (0.00). It may suggest that Hindustan Bio Sciences is progressively becoming less dependent on debt to grow their business.

Hindustan Bio Sciences LT-Debt-to-Total-Asset Historical Data

The historical data trend for Hindustan Bio Sciences's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hindustan Bio Sciences LT-Debt-to-Total-Asset Chart

Hindustan Bio Sciences Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.44

0.30

0.21

0.36

0.34

Hindustan Bio Sciences Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Sep23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.37	-	0.34	0.44	-

Hindustan Bio Sciences LT-Debt-to-Total-Asset Calculation

Hindustan Bio Sciences's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2023 is calculated as

LT Debt to Total Assets (A: Mar. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Mar. 2023 )	/	Total Assets (A: Mar. 2023 )
	=	11.219	/	32.866
	=	0.34

Hindustan Bio Sciences's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	0	/	0
	=

Hindustan Bio Sciences (BOM:532041) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Hindustan Bio Sciences LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Hindustan Bio Sciences's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Hindustan Bio Sciences (BOM:532041) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hindustan Bio Sciences Ltd (BOM:532041) » Definitions » LT-Debt-to-Total-Asset

Traded in Other Exchanges

N/A

Address

Road No. 2, Banjara Hills, H.No. 8-2-269/S, Plot No. 31, Sagar Co-Operative Housing Society, Hyderabad, TG, IND, 500034

Website

https://www.hindustanbiosciences.in

Hindustan Bio Sciences Ltd is an India-based company operating in the pharmaceutical and biotechnology sector. It is engaged in the trading of Drugs and Medicines. The company markets a nephrology product, Recombinant Human Erythropoietin, which is useful for the treatment of anemia associated with chronic renal failure. In addition, the firm also manufactures and markets pharmaceutical products in different forms such as tablets, capsules, drops, externals, and syrups. Its other formulations comprise Pantorest, Maxion, Edinil, Aromycin, Livohin and others. Geographically, the group sells its products within India and also exports it to other countries.

Hindustan Bio Sciences (BOM:532041) Headlines

No Headlines